Defining embryonic stem cell identity using differentiation-related microRNAs and their potential targets

Caifu Chen,Dana Ridzon,Chung-Tien Lee,Julie Blake,Y. Sun,W. Strauss

DOI: https://doi.org/10.1007/s00335-007-9032-6

2007-07-03

Mammalian Genome

Abstract:

What problem does this paper attempt to address?

Develop a Diagnostic Tool for Dementia Using Machine Learning and Non-Imaging Features

Huan Wang,Li Sheng,Shanhu Xu,Yu Jin,Xiaoqing Jin,Song Qiao,Qingqing Chen,Wenmin Xing,Zhenlei Zhao,Jing Yan,Genxiang Mao,Xiaogang Xu

DOI: https://doi.org/10.3389/fnagi.2022.945274

IF: 4.8

2022-01-01

Frontiers in Aging Neuroscience

Abstract:Background Early identification of Alzheimer’s disease or mild cognitive impairment can help guide direct prevention and supportive treatments, improve outcomes, and reduce medical costs. Existing advanced diagnostic tools are mostly based on neuroimaging and suffer from certain problems in cost, reliability, repeatability, accessibility, ease of use, and clinical integration. To address these problems, we developed, evaluated, and implemented an early diagnostic tool using machine learning and non-imaging factors. Methods and results A total of 654 participants aged 65 or older from the Nursing Home in Hangzhou, China were identified. Information collected from these patients includes dementia status and 70 demographic, cognitive, socioeconomic, and clinical features. Logistic regression, support vector machine (SVM), neural network, random forest, extreme gradient boosting (XGBoost), least absolute shrinkage and selection operator (LASSO), and best subset models were trained, tuned, and internally validated using a novel double cross validation algorithm and multiple evaluation metrics. The trained models were also compared and externally validated using a separate dataset with 1,100 participants from four communities in Zhejiang Province, China. The model with the best performance was then identified and implemented online with a friendly user interface. For the nursing dataset, the top three models are the neural network (AUROC = 0.9435), XGBoost (AUROC = 0.9398), and SVM with the polynomial kernel (AUROC = 0.9213). With the community dataset, the best three models are the random forest (AUROC = 0.9259), SVM with linear kernel (AUROC = 0.9282), and SVM with polynomial kernel (AUROC = 0.9213). The F1 scores and area under the precision-recall curve showed that the SVMs, neural network, and random forest were robust on the unbalanced community dataset. Overall the SVM with the polynomial kernel was found to be the best model. The LASSO and best subset models identified 17 features most relevant to dementia prediction, mostly from cognitive test results and socioeconomic characteristics. Conclusion Our non-imaging-based diagnostic tool can effectively predict dementia outcomes. The tool can be conveniently incorporated into clinical practice. Its online implementation allows zero barriers to its use, which enhances the disease’s diagnosis, improves the quality of care, and reduces costs.
Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms

Shashank Khanna,Daniel Domingo-Fernández,Anandhi Iyappan,Mohammad Asif Emon,Martin Hofmann-Apitius,Holger Fröhlich

DOI: https://doi.org/10.1038/s41598-018-29433-3

IF: 4.6

2018-07-24

Scientific Reports

Abstract:Alzheimer’s Disease (AD) is among the most frequent neuro-degenerative diseases. Early diagnosis is essential for successful disease management and chance to attenuate symptoms by disease modifying drugs. In the past, a number of cerebrospinal fluid (CSF), plasma and neuro-imaging based biomarkers have been proposed. Still, in current clinical practice, AD diagnosis cannot be made until the patient shows clear signs of cognitive decline, which can partially be attributed to the multi-factorial nature of AD. In this work, we integrated genotype information, neuro-imaging as well as clinical data (including neuro-psychological measures) from ~900 normal and mild cognitively impaired (MCI) individuals and developed a highly accurate machine learning model to predict the time until AD is diagnosed. We performed an in-depth investigation of the relevant baseline characteristics that contributed to the AD risk prediction. More specifically, we used Bayesian Networks to uncover the interplay across biological scales between neuro-psychological assessment scores, single genetic variants, pathways and neuro-imaging related features. Together with information extracted from the literature, this allowed us to partially reconstruct biological mechanisms that could play a role in the conversion of normal/MCI into AD pathology. This in turn may open the door to novel therapeutic options in the future.

multidisciplinary sciences
A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer’s disease

Shaker El-Sappagh,Jose M. Alonso,S. M. Riazul Islam,Ahmad M. Sultan,Kyung Sup Kwak

DOI: https://doi.org/10.1038/s41598-021-82098-3

IF: 4.6

2021-01-29

Scientific Reports

Abstract:Abstract Alzheimer’s disease (AD) is the most common type of dementia. Its diagnosis and progression detection have been intensively studied. Nevertheless, research studies often have little effect on clinical practice mainly due to the following reasons: (1) Most studies depend mainly on a single modality, especially neuroimaging; (2) diagnosis and progression detection are usually studied separately as two independent problems; and (3) current studies concentrate mainly on optimizing the performance of complex machine learning models, while disregarding their explainability. As a result, physicians struggle to interpret these models, and feel it is hard to trust them. In this paper, we carefully develop an accurate and interpretable AD diagnosis and progression detection model. This model provides physicians with accurate decisions along with a set of explanations for every decision. Specifically, the model integrates 11 modalities of 1048 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) real-world dataset: 294 cognitively normal, 254 stable mild cognitive impairment (MCI), 232 progressive MCI, and 268 AD. It is actually a two-layer model with random forest (RF) as classifier algorithm. In the first layer, the model carries out a multi-class classification for the early diagnosis of AD patients. In the second layer, the model applies binary classification to detect possible MCI-to-AD progression within three years from a baseline diagnosis. The performance of the model is optimized with key markers selected from a large set of biological and clinical measures. Regarding explainability, we provide, for each layer, global and instance-based explanations of the RF classifier by using the SHapley Additive exPlanations (SHAP) feature attribution framework. In addition, we implement 22 explainers based on decision trees and fuzzy rule-based systems to provide complementary justifications for every RF decision in each layer. Furthermore, these explanations are represented in natural language form to help physicians understand the predictions. The designed model achieves a cross-validation accuracy of 93.95% and an F1-score of 93.94% in the first layer, while it achieves a cross-validation accuracy of 87.08% and an F1-Score of 87.09% in the second layer. The resulting system is not only accurate, but also trustworthy, accountable, and medically applicable, thanks to the provided explanations which are broadly consistent with each other and with the AD medical literature. The proposed system can help to enhance the clinical understanding of AD diagnosis and progression processes by providing detailed insights into the effect of different modalities on the disease risk.

multidisciplinary sciences
A robust and clinically applicable deep learning model for early detection of Alzheimer's

Masud Rana,Manowarul Islam,Alamin Talukder,Ashraf Uddin,Sunil Aryal,Naif Alotaibi,Salem A. Alyami,Khondokar Fida Hasan,Mohammad Ali Moni,Md Masud Rana,Md Manowarul Islam,Md. Alamin Talukder,Md Ashraf Uddin

DOI: https://doi.org/10.1049/ipr2.12910

IF: 2.3

2023-09-06

IET Image Processing

Abstract:Alzheimer's disease is a severe neurodegenerative disorder causing irreversible memory loss and is most common among seniors 65 years and older. Early diagnosis can slow its progress. Artificial intelligence, particularly deep and machine learning models, can help with diagnosis by identifying subtle patterns in extensive patient datasets. A new Hybrid CNN methodology using brain MRI images and transfer learning for multi‐class classification achieves 97.31% accuracy and outperforms state‐of‐the‐art models in accuracy, precision, recall and F‐score. Alzheimer's disease, often known as dementia, is a severe neurodegenerative disorder that causes irreversible memory loss by destroying brain cells. People die because there is no specific treatment for this disease. Alzheimer's is most common among seniors 65 years and older. However, the progress of this disease can be reduced if it can be diagnosed earlier. Recently, artificial intelligence has instilled hope in the diagnosis of Alzheimer's disease by performing sophisticated analyses on extensive patient datasets, enabling the identification of subtle patterns that may elude human experts. Researchers have investigated various deep learning and machine learning models to diagnose this disease at an early stage using image datasets. In this paper, a new Deep learning (DL) methodology is proposed, where MRI images are fed into the model after applying various pre‐processing techniques. The proposed Alzheimer's disease detection approach adopts transfer learning for multi‐class classification using brain MRIs. The MRI Images are classified into four categories: mild dementia (MD), moderate dementia (MOD), very mild dementia (VMD), and non‐dementia (ND). The model is implemented and extensive performance analysis is performed. The finding shows that the model obtains 97.31% accuracy. The model outperforms the state‐of‐the‐art models in terms of accuracy, precision, recall, and F‐score.

computer science, artificial intelligence,engineering, electrical & electronic,imaging science & photographic technology
Application of Machine Learning to Predict the Risk of Alzheimer's Disease: An Accurate and Practical Solution for Early Diagnostics

Courtney Cochrane,David Castineira,Nisreen Shiban,Pavlos Protopapas

DOI: https://doi.org/10.48550/arXiv.2006.08702

2020-06-02

Abstract:Alzheimer's Disease (AD) ravages the cognitive ability of more than 5 million Americans and creates an enormous strain on the health care system. This paper proposes a machine learning predictive model for AD development without medical imaging and with fewer clinical visits and tests, in hopes of earlier and cheaper diagnoses. That earlier diagnoses could be critical in the effectiveness of any drug or medical treatment to cure this disease. Our model is trained and validated using demographic, biomarker and cognitive test data from two prominent research studies: Alzheimer's Disease Neuroimaging Initiative (ADNI) and Australian Imaging, Biomarker Lifestyle Flagship Study of Aging (AIBL). We systematically explore different machine learning models, pre-processing methods and feature selection techniques. The most performant model demonstrates greater than 90% accuracy and recall in predicting AD, and the results generalize across sub-studies of ADNI and to the independent AIBL study. We also demonstrate that these results are robust to reducing the number of clinical visits or tests per visit. Using a metaclassification algorithm and longitudinal data analysis we are able to produce a "lean" diagnostic protocol with only 3 tests and 4 clinical visits that can predict Alzheimer's development with 87% accuracy and 79% recall. This novel work can be adapted into a practical early diagnostic tool for predicting the development of Alzheimer's that maximizes accuracy while minimizing the number of necessary diagnostic tests and clinical visits.

Quantitative Methods,Machine Learning
Machine learning in Alzheimer's disease drug discovery and target identification

Chaofan Geng,ZhiBin Wang,Yi Tang

DOI: https://doi.org/10.1016/j.arr.2023.102172

Abstract:Alzheimer's disease (AD) stands as a formidable neurodegenerative ailment that poses a substantial threat to the elderly population, with no known curative or disease-slowing drugs in existence. Among the vital and time-consuming stages in the drug discovery process, disease modeling and target identification hold particular significance. Disease modeling allows for a deeper comprehension of disease progression mechanisms and potential therapeutic avenues. On the other hand, target identification serves as the foundational step in drug development, exerting a profound influence on all subsequent phases and ultimately determining the success rate of drug development endeavors. Machine learning (ML) techniques have ushered in transformative breakthroughs in the realm of target discovery. Leveraging the strengths of large dataset analysis, multifaceted data processing, and the exploration of intricate biological mechanisms, ML has become instrumental in the quest for effective AD treatments. In this comprehensive review, we offer an account of how ML methodologies are being deployed in the pursuit of drug discovery for AD. Furthermore, we provide an overview of the utilization of ML in uncovering potential intervention strategies and prospective therapeutic targets for AD. Finally, we discuss the principal challenges and limitations currently faced by these approaches. We also explore the avenues for future research that hold promise in addressing these challenges.
A Transcriptomics-Based Machine Learning Model Discriminating Mild Cognitive Impairment and the Prediction of Conversion to Alzheimer's Disease

Min-Koo Park,Jinhyun Ahn,Jin-Muk Lim,Minsoo Han,Ji-Won Lee,Jeong-Chan Lee,Sung-Joo Hwang,Keun-Cheol Kim

DOI: https://doi.org/10.3390/cells13221920

IF: 6

2024-11-27

Cells

Abstract:The clinical spectrum of Alzheimer's disease (AD) ranges dynamically from asymptomatic and mild cognitive impairment (MCI) to mild, moderate, or severe AD. Although a few disease-modifying treatments, such as lecanemab and donanemab, have been developed, current therapies can only delay disease progression rather than halt it entirely. Therefore, the early detection of MCI and the identification of MCI patients at high risk of progression to AD remain urgent unmet needs in the super-aged era. This study utilized transcriptomics data from cognitively unimpaired (CU) individuals, MCI, and AD patients in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort and leveraged machine learning models to identify biomarkers that differentiate MCI from CU and also distinguish AD from MCI individuals. Furthermore, Cox proportional hazards analysis was conducted to identify biomarkers predictive of the progression from MCI to AD. Our machine learning models identified a unique set of gene expression profiles capable of achieving an area under the curve (AUC) of 0.98 in distinguishing those with MCI from CU individuals. A subset of these biomarkers was also found to be significantly associated with the risk of progression from MCI to AD. A linear mixed model demonstrated that plasma tau phosphorylated at threonine 181 (pTau181) and neurofilament light chain (NFL) exhibit the prognostic value in predicting cognitive decline longitudinally. These findings underscore the potential of integrating machine learning (ML) with transcriptomic profiling in the early detection and prognostication of AD. This integrated approach could facilitate the development of novel diagnostic tools and therapeutic strategies aimed at delaying or preventing the onset of AD in at-risk individuals. Future studies should focus on validating these biomarkers in larger, independent cohorts and further investigating their roles in AD pathogenesis.

cell biology
An explainable machine learning approach for Alzheimer's disease classification

Abbas Saad Alatrany,Wasiq Khan,Abir Hussain,Hoshang Kolivand,Dhiya Al-Jumeily

DOI: https://doi.org/10.1038/s41598-024-51985-w

IF: 4.6

2024-02-02

Scientific Reports

Abstract:The early diagnosis of Alzheimer's disease (AD) presents a significant challenge due to the subtle biomarker changes often overlooked. Machine learning (ML) models offer a promising tool for identifying individuals at risk of AD. However, current research tends to prioritize ML accuracy while neglecting the crucial aspect of model explainability. The diverse nature of AD data and the limited dataset size introduce additional challenges, primarily related to high dimensionality. In this study, we leveraged a dataset obtained from the National Alzheimer's Coordinating Center, comprising 169,408 records and 1024 features. After applying various steps to reduce the feature space. Notably, support vector machine (SVM) models trained on the selected features exhibited high performance when tested on an external dataset. SVM achieved a high F1 score of 98.9% for binary classification (distinguishing between NC and AD) and 90.7% for multiclass classification. Furthermore, SVM was able to predict AD progression over a 4-year period, with F1 scores reached 88% for binary task and 72.8% for multiclass task. To enhance model explainability, we employed two rule-extraction approaches: class rule mining and stable and interpretable rule set for classification model. These approaches generated human-understandable rules to assist domain experts in comprehending the key factors involved in AD development. We further validated these rules using SHAP and LIME models, underscoring the significance of factors such as MEMORY, JUDGMENT, COMMUN, and ORIENT in determining AD risk. Our experimental outcomes also shed light on the crucial role of the Clinical Dementia Rating tool in predicting AD.

multidisciplinary sciences
A hybrid multimodal machine learning model for Detecting Alzheimer's disease

Jinhua Sheng,Qian Zhang,Qiao Zhang,Luyun Wang,Ze Yang,Yu Xin,Binbing Wang

DOI: https://doi.org/10.1016/j.compbiomed.2024.108035

IF: 7.7

2024-03-01

Computers in Biology and Medicine

Abstract:Alzheimer's disease (AD) diagnosis utilizing single modality neuroimaging data has limitations. Multimodal fusion of complementary biomarkers may improve diagnostic performance. This study proposes a multimodal machine learning framework integrating magnetic resonance imaging (MRI), positron emission tomography (PET) and cerebrospinal fluid (CSF) assays for enhanced AD characterization. The model incorporates a hybrid algorithm combining enhanced Harris Hawks Optimization (HHO) algorithm referred to as ILHHO, with Kernel Extreme Learning Machine (KELM) classifier for simultaneous feature selection and classification. ILHHO enhances HHO's search efficiency by integrating iterative mapping (IM) to improve population diversity and local escaping operator (LEO) to balance exploration-exploitation. Comparative analysis with other improved HHO algorithms, classic meta-heuristic algorithms (MHAs), and state-of-the-art MHAs on IEEE CEC2014 benchmark functions indicates that ILHHO achieves superior optimization performance compared to other comparative algorithms. The synergistic ILHHO-KELM model is evaluated on 202 AD Neuroimaging Initiative (ADNI) subjects. Results demonstrate superior multimodal classification accuracy over single modalities, validating the importance of fusing heterogeneous biomarkers. MRI + PET + CSF achieves 99.2 % accuracy for AD vs. normal control (NC), outperforming conventional and proposed methods. Discriminative feature analysis provides further insights into differential AD-related neurodegeneration patterns detected by MRI and PET. The differential PET and MRI features demonstrate how the two modalities provide complementary biomarkers. The neuroanatomical relevance of selected features supports ILHHO-KELM's potential for extracting sensitive AD imaging signatures. Overall, the study showcases the advantages of capitalizing on complementary multimodal data through advanced feature learning techniques for improving AD diagnosis.

engineering, biomedical,computer science, interdisciplinary applications,mathematical & computational biology,biology
Early-Stage Alzheimer's Disease Prediction Using Machine Learning Models

C. Kavitha,Vinodhini Mani,S. R. Srividhya,Osamah Ibrahim Khalaf,Carlos Andrés Tavera Romero

DOI: https://doi.org/10.3389/fpubh.2022.853294

IF: 5.2

2022-03-03

Frontiers in Public Health

Abstract:Alzheimer's disease (AD) is the leading cause of dementia in older adults. There is currently a lot of interest in applying machine learning to find out metabolic diseases like Alzheimer's and Diabetes that affect a large population of people around the world. Their incidence rates are increasing at an alarming rate every year. In Alzheimer's disease, the brain is affected by neurodegenerative changes. As our aging population increases, more and more individuals, their families, and healthcare will experience diseases that affect memory and functioning. These effects will be profound on the social, financial, and economic fronts. In its early stages, Alzheimer's disease is hard to predict. A treatment given at an early stage of AD is more effective, and it causes fewer minor damage than a treatment done at a later stage. Several techniques such as Decision Tree, Random Forest, Support Vector Machine, Gradient Boosting, and Voting classifiers have been employed to identify the best parameters for Alzheimer's disease prediction. Predictions of Alzheimer's disease are based on Open Access Series of Imaging Studies (OASIS) data, and performance is measured with parameters like Precision, Recall, Accuracy, and F1-score for ML models. The proposed classification scheme can be used by clinicians to make diagnoses of these diseases. It is highly beneficial to lower annual mortality rates of Alzheimer's disease in early diagnosis with these ML algorithms. The proposed work shows better results with the best validation average accuracy of 83% on the test data of AD. This test accuracy score is significantly higher in comparison with existing works.

public, environmental & occupational health
Advancing Early Diagnostic Accuracy for Alzheimer s Disease Through the Integration of Machine and Deep Learning Paradigms by Applying Multisource Datasets

Rashmi Kumari,Tanzel Ahmad,Arnav Talaan,Vishal Gola,Subhranil Das,Raghwendra Kishore Singh

DOI: https://doi.org/10.58190/icisna.2024.88

2024-04-28

Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder with a critical need for early and accurate diagnosis. In this research, various machine learning (ML) and deep learning (DL) techniques are employed for identifying reliable biomarkers for early-stage AD detection. This research paper presents a comprehensive approach utilizing a myriad of artificial intelligence (AI) and machine learning (ML), i.e., self-attention mechanisms with Convolutional Neural Networks (CNN) model has been proposed for predicting the onset of AD. The study has compared these models including Gaussian Naive Bayes (GNB), Decision Trees (DT), Random Forest (RF), XGBoost, Voting Classifier (VC) where the proposed Feature based CNN (F-CNN) network produces the highest classification accuracy, sensitivity, recall, AUC and F1 scores by utilizing datasets such as the Alzheimer's Disease Neuroimaging Initiative (ADNI). The proposed approach holds promise for early detection and intervention in AD, potentially enabling clinicians to intervene before the onset of clinical symptoms. The findings of this research could significantly contribute to improving patient outcomes and advancing our understanding of Alzheimer's disease pathology.
Predicting early Alzheimer's with blood biomarkers and clinical features

Muaath Ebrahim AlMansoori,Sherlyn Jemimah,Ferial Abuhantash,Aamna AlShehhi

DOI: https://doi.org/10.1038/s41598-024-56489-1

IF: 4.6

2024-03-14

Scientific Reports

Abstract:Alzheimer's disease (AD) is an incurable neurodegenerative disorder that leads to dementia. This study employs explainable machine learning models to detect dementia cases using blood gene expression, single nucleotide polymorphisms (SNPs), and clinical data from Alzheimer's Disease Neuroimaging Initiative (ADNI). Analyzing 623 ADNI participants, we found that the Support Vector Machine classifier with Mutual Information (MI) feature selection, trained on all three data modalities, achieved exceptional performance (accuracy = 0.95, AUC = 0.94). When using gene expression and SNP data separately, we achieved very good performance (AUC = 0.65, AUC = 0.63, respectively). Using SHapley Additive exPlanations (SHAP), we identified significant features, potentially serving as AD biomarkers. Notably, genetic-based biomarkers linked to axon myelination and synaptic vesicle membrane formation could aid early AD detection. In summary, this genetic-based biomarker approach, integrating machine learning and SHAP, shows promise for precise AD diagnosis, biomarker discovery, and offers novel insights for understanding and treating the disease. This approach addresses the challenges of accurate AD diagnosis, which is crucial given the complexities associated with the disease and the need for non-invasive diagnostic methods.

multidisciplinary sciences
Exploring the power of MRI and clinical measures in predicting Alzheimers disease neuropathology

Farooq Kamal,Cassandra Morrison,Michael D. Oliver,Mahsa Dadar

DOI: https://doi.org/10.1101/2024.07.09.24310163

2024-07-10

Abstract:Background: The ability to predict Alzheimers disease (AD) before diagnosis is a topic of intense research. Early diagnosis would aid in improving treatment and intervention options, however, there are no current methods that can accurately predict AD years in advance. This study examines a novel machine learning approach that integrates the combined effects of vascular (white matter hyperintensities, WMHs), and structural brain changes (gray matter, GM) with clinical factors (cognitive status) to predict post-mortem neuropathological outcomes. Methods: Healthy older adults, participants with mild cognitive impairment, and AD from the Alzheimer's Disease Neuroimaging Initiative dataset with both post-mortem neuropathology data and antemortem MRI and clinical data were included. Longitudinal data were analyzed across three intervals before death (post-mortem data): 0-4 years, 4-8 years, and 8-14 years. Additionally, cross-sectional data at the last visit or interval (within four years, 0-4 years) before death were also examined. Machine learning models including gradient boosting, bagging, support vector regression, and linear regression were implemented. These models were applied towards feature selection of the top seven MRI, clinical, and demographic data to identify the best performing set of variables that could predict postmortem neuropathology outcomes (i.e., neurofibrillary tangles, neuritic plaques, diffuse plaques, senile/amyloid plaques, and amyloid angiopathy). Results: A total of 94 participants (55-90 years of age) were included in the study. At last visit, the best-performing model included total and temporal lobe WMHs and achieved r=0.87(RMSE=0.62) during cross-validation for neuritic plaques. For longitudinal assessments across different intervals, the best-performing model included regional GM (i.e., hippocampus, amygdala, caudate) and frontal lobe WMH and achieved r=0.93(RMSE=0.59) during cross-validation for neurofibrillary tangles. For MRI and clinical predictors and clinical-only predictors, t-tests demonstrated significant differences at all intervals before death (t[-13.60-7.90], p-values<0.001). Overall, post-mortem neuropathology outcome were predicted up to 14 years before death with high accuracies (~90%). Conclusions: Prediction accuracy was higher for post-mortem neuropathology outcomes that included MRI (WMHs, GM) and clinical features compared to clinical-only features. These findings highlight that MRI features are critical to successfully predict AD-related pathology years in advance which will improve participant selection for clinical trials, treatments, and intervention options.

Pathology
A Novel Approach Utilizing Machine Learning for the Early Diagnosis of Alzheimer's Disease

Khandaker Mohammad Mohi Uddin,Mir Jafikul Alam,Jannat-E-Anawar,Md Ashraf Uddin,Sunil Aryal

DOI: https://doi.org/10.1007/s44174-023-00078-9

2023-04-12

Biomedical Materials & Devices

Abstract:Alzheimer's disease (AD) is one of the leading causes of dementia among older people. In addition, a considerable portion of the world's population suffers from metabolic problems, such as Alzheimer's disease and diabetes. Alzheimer's disease affects the brain in a degenerative manner. As the elderly population grows, this illness can cause more people to become inactive by impairing their memory and physical functionality. This might impact their family members and the financial, economic, and social spheres. Researchers have recently investigated different machine learning and deep learning approaches to detect such diseases at an earlier stage. Early diagnosis and treatment of AD help patients to recover from it successfully and with the least harm. This paper proposes a machine learning model that comprises GaussianNB, Decision Tree, Random Forest, XGBoost, Voting Classifier, and GradientBoost to predict Alzheimer's disease. The model is trained using the open access series of imaging studies (OASIS) dataset to evaluate the performance in terms of accuracy, precision, recall, and F1 score. Our findings showed that the voting classifier attained the highest validation accuracy of 96% for the AD dataset. Therefore, ML algorithms have the potential to drastically lower Alzheimer's disease annual mortality rates through accurate detection.
A quantitative analysis of Alzheimers Disease and construction of an early Alzheimers detection deep learning system (EADDLS) using MRI data via machine learning along with ADmod: spatiotemporal-aware brain-amyloidβ growth model, using deep encoder-decoder networks about MRI

Naitik Mohanty,Morteza Sarmadi

DOI: https://doi.org/10.1101/2024.08.02.24311435

2024-08-07

Abstract:Alzheimer's disease (AD) presents a significant societal challenge, with no current cure and an increasing prevalence among older adults. This study addresses the pressing need for early detection by harnessing the potential of machine learning applied to longitudinal MRI data. The dataset, sourced from the Open Access Series of Imaging Studies (OASIS) project, comprises MRI records of 150 subjects aged 60 to 96, each scanned at least once. Notably, 72 subjects were classified as 'Nondemented,' 64 as 'Demented,' and 14 underwent a transition from 'Nondemented' to 'Demented,' forming the 'Converted' category. What we propose is to develop a machine learning sound model capable of predicting the progression of mild cognitive impairment, leveraging key biomarkers extracted from MRI data. The chosen biomarkers include years of education (EDUC), socioeconomic status (SES), Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Estimated Total Intracranial Volume (eTIV), Normalized Whole Brain Volume (nWBV), and Atlas Scaling Factor (ASF). Prior work in the field is referenced, highlighting studies that predominantly focused on raw MRI data analysis. In contrast, this study introduces a unique approach by utilizing a curated set of biomarkers, allowing for a more targeted and potentially interpretable model. Machine learning models such as Logistic Regression, Support Vector Machine, Decision Tree, Random Forest Classifier, and AdaBoost are employed, with performance measured using established metrics. Information about severity and state are stored during the EADDLS module and used for ADmod. ADmod uses the stored MRI data during the EADDLS module to model the growth of amyloid β build-up in the brain using convolution, resulting in both generalizable approaches and patient-specific approaches. There have been numerous mathematical instantiations to model amyloid β build-up using partial differential equations (or PDEs), these however have remained unincorporated due to prolonged runtimes and storage limitations along with those of pre-set conditions. We propose a novel amyloid β growth model using deep encoder-decoder networks in conjunction with convolution. The study contributes to the growing body of research in early Alzheimer's detection, offering insights, results, and a discussion of limitations. The conclusion outlines a unique approach, emphasizes the practical implementation of the proposed model, acknowledges limitations, and suggests avenues for further research. Early detection of AD can significantly better the patient's quality of care and lead to future preventative or risk assessment measures.

Radiology and Imaging
Alzheimer's disease diagnosis framework from incomplete multimodal data using convolutional neural networks

Mohammed Abdelaziz,Tianfu Wang,Ahmed Elazab

DOI: https://doi.org/10.1016/j.jbi.2021.103863

Abstract:Alzheimer's disease (AD) is a severe irreversible neurodegenerative disease that has great sufferings on patients and eventually leads to death. Early detection of AD and its prodromal stage, mild cognitive impairment (MCI) which can be either stable (sMCI) or progressive (pMCI), is highly desirable for effective treatment planning and tailoring therapy. Recent studies recommended using multimodal data fusion of genetic (single nucleotide polymorphisms, SNPs) and neuroimaging data (magnetic resonance imaging (MRI) and positron emission tomography (PET)) to discriminate AD/MCI from normal control (NC) subjects. However, missing multimodal data in the cohort under study is inevitable. In addition, data heterogeneity between phenotypes and genotypes biomarkers makes learning capability of the models more challenging. Also, the current studies mainly focus on identifying brain disease classification and ignoring the regression task. Furthermore, they utilize multistage for predicting the brain disease progression. To address these issues, we propose a novel multimodal neuroimaging and genetic data fusion for joint classification and clinical score regression tasks using the maximum number of available samples in one unified framework using convolutional neural network (CNN). Specifically, we initially perform a technique based on linear interpolation to fill the missing features for each incomplete sample. Then, we learn the neuroimaging features from MRI, PET, and SNPs using CNN to alleviate the heterogeneity among genotype and phenotype data. Meanwhile, the high learned features from each modality are combined for jointly identifying brain diseases and predicting clinical scores. To validate the performance of the proposed method, we test our method on 805 subjects from Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset. Also, we verify the similarity between the synthetic and real data using statistical analysis. Moreover, the experimental results demonstrate that the proposed method can yield better performance in both classification and regression tasks. Specifically, our proposed method achieves accuracy of 98.22%, 93.11%, and 97.35% for NC vs. AD, NC vs. sMCI, and NC vs. pMCI, respectively. On the other hand, our method attains the lowest root mean square error and the highest correlation coefficient for different clinical scores regression tasks compared with the state-of-the-art methods.
Anticoagulation experts assess practical effects of new heparin potency assay.

C. Thompson

DOI: https://doi.org/10.2146/news090084

2009-11-15

American Journal of Health-System Pharmacy

Abstract:When an FDA official announced October 1 that health care providers should prepare for the arrival of heparin products that may be about 10% less potent than what was already in use, the message lacked explicit instructions. “Clinicians,” said John K. Jenkins, director of FDA’s Office of New
Multimodal Data Integration for Early Alzheimer’s Detection Using Random Forest and Support Vector Machines

Muhammad Nadeem,Wei Zhang,Sarwat Aslam,Liaqat Ali,Abdul Majid

DOI: https://doi.org/10.32628/cseit241047

2024-07-22

Abstract:Alzheimer's is a very challenging brain disease to recognize, diagnose, and treat correctly when it appears in its earliest forms. The primary contribution of this research study is about machine learning models, techniques, and approaches. In contrast, Random Forest and Support Vector Machine (SVM) are particularly suitable for identifying and staging Alzheimer's disease stages using multimodal data sources. In this paper, the aim was to develop well-performing predictive models to help diagnose Alzheimer's disease at an early stage by combining neuroimaging data (MRI/PET images), imaging-based biomarkers, both structural and functional measures from MRI(P) /PET image analysis along with subject-specific demographics like age using clinical features in a probabilistic fashion obtained from the Alzheimer's Disease Neuro-Imaging Initiative (ADNI) database. The methodology focuses on data pre-processing, feature selection, and model building using supervised learning algorithms. The accuracy of the Random Forest model is 78%, having a high performance in classifying some classes while showing different marks of performances across other courses. SVM reached an accuracy of 61%, or the model's performance is good in some classes and not reliable to identify samples from the others. The findings of this study underscore the capabilities and limits of these machine learning models in identifying Alzheimer’s disease and highlight the importance of feature engineering, data pre-processing, and model tuning to increase performance and correct class unevenness and misclassification.
Deep Neural Network Classifier for Alzheimer’s Disease

Jason Lin,Hayan Lee,Michael Snyder

DOI: https://doi.org/10.47611/jsrhs.v11i3.3553

2022-08-31

Journal of Student Research

Abstract:Alzheimer's disease (AD) is a neurodegenerative disease characterized by dementia and, eventually, a loss of cognitive abilities. Two histopathological features are associated with AD, neurofibrillary tangles, and amyloid-beta plaque. Both contribute to neuron cell death, neuron dysfunction, and AD pathogenesis. Current methods to diagnose AD remain reliant on symptomatic diagnosis with interviews that can be time-consuming, costly, and inaccurate. Alternative methods such as brain imaging are expensive and require extensive laboratory setup for accurate results. Thus molecular-level quantitative approaches are necessary. Omics datasets and machine learning technology advancements have opened new avenues to diagnose AD. This paper proposes using statistical methods such as principal component analysis, t-distributed stochastic neighbor embedding, and Kolmogorov-Smirnov test combined with Benjamini-Hochberg correction through feature selection and dimensionality reduction to isolate significant features associated with AD. Furthermore, we developed machine learning models based on logistic regression, random forest classifier, and deep neural network (DNN) classifier to predict AD diagnosis. Eight unique genes (TGM2, NKIRAS1, SYK, GABARAPL2, ABCC12, NDEL1, TEP1) were identified as significant biomarkers of AD and confirmed previous works identifying prognoses' roles in AD. After extensive hyperparameter tuning, the DNN model showed the best prediction performance for AD diagnosis among the three machine learning algorithms. The DNN model and preprocessed dataset demonstrated a 5-fold cross-validation accuracy of 0.823 and AUC-ROC of 0.940. Its code is publicly available at https://www.kaggle.com/neobrando/ml-dnn.
Dual Attention Convolutional AutoEncoder for Diagnosis of Alzheimer's Disorder in Patients Using Neuroimaging and MRI Features

Shaha Al-Otaibi,Muhammad Mujahid,Amjad Rehman Khan,Haitham Nobanee,Jaber Alyami,Tanzila Saba

DOI: https://doi.org/10.1109/access.2024.3390186

IF: 3.9

2024-05-03

IEEE Access

Abstract:Alzheimer's disease is a neurodegenerative disease causing memory loss and brain protein accumulation. Early diagnosis is crucial for clinical trials and patient care. Magnetic resonance imaging (MRI) methods have improved diagnosis and prognosis, but doctors need to interpret images proficiently. Deep learning technology has shown potential in detecting Alzheimer's disease, but the disease progresses slower in early phases. A new dual-attention convolutional autoencoder model is presented, offering improved detection abilities and potential for real-time use in Alzheimer's disease diagnosis. The study utilized two datasets: the first ADNI dataset, which includes three classes (MCI, CN, and AD), and the second Alzheimer's Disease Neuroimaging Dataset, which includes two distinct classes (AD and MCI). We analyze the effectiveness of our proposed model by evaluating key performance metrics such as accuracy, precision, sensitivity, specificity, F1 score, and AUC score. In addition, we utilize cross-validation and mean absolute error to validate our model while also fine-tuning the parameters. Based on experimental data, the proposed model accurately detected Alzheimer's disease with an accuracy of 0.9902 ± 0.0139. Based on the results, the proposed model demonstrates excellent performance compared to the existing methods described in the literature. The proposed mode achieves precision, sensitivity, and specificity of 0.9882 ± 0.0587, 0.9898 ± 0.0865, 0.9912 ± 0.0872 respectively. The model achieved an AUC score of 0.9992 for MCI and 0.9919 for AD class. Furthermore, the proposed method can enhance the affordability of Alzheimer's disease diagnostics and increase the rate of early AD detection by facilitating remote healthcare.

computer science, information systems,telecommunications,engineering, electrical & electronic

Defining embryonic stem cell identity using differentiation-related microRNAs and their potential targets

Develop a Diagnostic Tool for Dementia Using Machine Learning and Non-Imaging Features

Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Biological Mechanisms

A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer’s disease

A robust and clinically applicable deep learning model for early detection of Alzheimer's

Application of Machine Learning to Predict the Risk of Alzheimer's Disease: An Accurate and Practical Solution for Early Diagnostics

Machine learning in Alzheimer's disease drug discovery and target identification

A Transcriptomics-Based Machine Learning Model Discriminating Mild Cognitive Impairment and the Prediction of Conversion to Alzheimer's Disease

An explainable machine learning approach for Alzheimer's disease classification

A hybrid multimodal machine learning model for Detecting Alzheimer's disease

Early-Stage Alzheimer's Disease Prediction Using Machine Learning Models

Advancing Early Diagnostic Accuracy for Alzheimer s Disease Through the Integration of Machine and Deep Learning Paradigms by Applying Multisource Datasets

Predicting early Alzheimer's with blood biomarkers and clinical features

Exploring the power of MRI and clinical measures in predicting Alzheimers disease neuropathology

A Novel Approach Utilizing Machine Learning for the Early Diagnosis of Alzheimer's Disease

A quantitative analysis of Alzheimers Disease and construction of an early Alzheimers detection deep learning system (EADDLS) using MRI data via machine learning along with ADmod: spatiotemporal-aware brain-amyloidβ growth model, using deep encoder-decoder networks about MRI

Alzheimer's disease diagnosis framework from incomplete multimodal data using convolutional neural networks

Anticoagulation experts assess practical effects of new heparin potency assay.

Multimodal Data Integration for Early Alzheimer’s Detection Using Random Forest and Support Vector Machines

Deep Neural Network Classifier for Alzheimer’s Disease

Dual Attention Convolutional AutoEncoder for Diagnosis of Alzheimer's Disorder in Patients Using Neuroimaging and MRI Features